|
|
A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer
|
|
|
|
|
نویسنده
|
hasegawa t. ,futamura y. ,horiba a. ,yoshida t. ,suzuki t. ,kato t. ,kaito d. ,ohno y. ,iida t. ,hayashi s. ,sawa t.
|
منبع
|
journal of radiation research - 2016 - دوره : 57 - شماره : 1 - صفحه:50 -54
|
چکیده
|
We investigated the efficacy and safety of albumin-bound paclitaxel (nab-ptx) and carboplatin (cbdca) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (nsclc). patients with stage iii nsclc and an eastern cooperative oncology group performance status of 0 or 1 were eligible. concurrent chemoradiotherapy consisted of weekly administration of nab-ptx (40 mg/m2) plus cbdca (area under the plasma concentration time curve (auc) 2) and thoracic radiotherapy (60 gy/30 fractions) for a total of 6 weeks. after concurrent chemoradiotherapy,patients received an additional two cycles of consolidation phase chemotherapy that consisted of 4-week cycles of nab-ptx (100 mg/m2 on days 1,8 and 15)/cbdca (auc 5 mg/ml/min on day 1). response was evaluated in accordance with the response evaluation criteria in solid tumors. progression-free survival and overall survival were estimated using the kaplan-meier method. toxicity was graded using the national cancer institute common terminology criteria for adverse events. a total of 10 patients were enrolled in this trial between september 2013 and january 2014 from three institutes. the overall response rate was 40.0% and the median progression-free survival was 6.7 months. treatment-related death occurred in two patients. grade 2 or worse severe radiation pneumonitis was observed in all three patients that had the volume of lung receiving at least 20 gy (v20) >30%. the results of this study indicate that no further investigation is warranted into nab-ptx and cbdca with concurrent thoracic radiation for stage iii nsclc with v20 > 30% due to severe toxicity. © 2015 the author 2015.
|
کلیدواژه
|
Carboplatin; Nab-paclitaxel; Non-small-cell lung cancer; Radiotherapy
|
آدرس
|
department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, respirtory medicine,national hospital organization nagara medical center,1300-7,nagara,gifu-shi,gifu 502-8558, Japan, respirtory medicine,national hospital organization nagara medical center,1300-7,nagara,gifu-shi,gifu 502-8558, Japan, department of respirology,gifu university graduate school of medicine,1-1 yanagido,gifu-shi,gifu 501-1194, Japan, department of respirology,gifu university graduate school of medicine,1-1 yanagido,gifu-shi,gifu 501-1194, Japan, department of radiology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of radiology,gifu university graduate school of medicine,1-1 yanagido,gifu-shi,gifu 501-1194, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|